Sector News

Global green light for Merck KGaA/Sigma merger

August 12, 2015
Life sciences
Merck KGaA has been granted unconditional permission by regulatory authorities in Brazil to purchase US life sciences group Sigma-Aldrich, which means the firm has now secured approvals from all relevant jurisdictions for its planned acquisition.
 
The German drugmaker said it expects to complete the transaction sometime in the third quarter of this year, creating a business with combined sales of 4.7 billion euros (based on 2013 financials).
 
The timeframe for deal completion has been slightly extended to allow commitments made to the European Commission under its conditional approval of the deal – i.e. the sale of parts of Sigma-Aldrich’s solvents and inorganics business in the region – to be met.
 
The companies first unveiled their $17 billion merger in September last year, in a move to establish “one of the leading players in the $130 billion global life science industry,” with the ability to offer customers “a highly attractive set of established brands and an efficient supply chain that can support the delivery of more than 300,000 products”, according to Merck.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend